Charles Schwab Investment Management Inc Coherus Bio Sciences, Inc. Transaction History
Charles Schwab Investment Management Inc
- $521 Billion
- Q1 2025
A detailed history of Charles Schwab Investment Management Inc transactions in Coherus Bio Sciences, Inc. stock. As of the latest transaction made, Charles Schwab Investment Management Inc holds 950,676 shares of CHRS stock, worth $922,155. This represents 0.0% of its overall portfolio holdings.
Number of Shares
950,676
Previous 976,857
2.68%
Holding current value
$922,155
Previous $1.35 Million
42.88%
% of portfolio
0.0%
Previous 0.0%
Shares
31 transactions
Others Institutions Holding CHRS
# of Institutions
120Shares Held
64.4MCall Options Held
96.6KPut Options Held
65.3K-
Black Rock Inc. New York, NY11.8MShares$11.4 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA11.2MShares$10.8 Million0.0% of portfolio
-
Rubric Capital Management LP New York, NY5.26MShares$5.1 Million0.12% of portfolio
-
Tang Capital Management LLC San Diego, CA5.1MShares$4.94 Million0.27% of portfolio
-
Kohlberg Kravis Roberts & Co. L.P. New York, NY3.04MShares$2.94 Million0.11% of portfolio
About Coherus BioSciences, Inc.
- Ticker CHRS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 77,724,600
- Market Cap $75.4M
- Description
- Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilar and immuno-oncology market primarily in the United States. The company markets UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte stimulating colony factor in the United States. Its pipeline products include biosimilars of Humira, Avastin, and Lucentis. T...